These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 26862829)

  • 1. Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study.
    Nasser AF; Henderson DC; Fava M; Fudala PJ; Twumasi-Ankrah P; Kouassi A; Heidbreder C
    J Clin Psychopharmacol; 2016 Apr; 36(2):130-40. PubMed ID: 26862829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monthly Extended-Release Risperidone (RBP-7000) in the Treatment of Schizophrenia: Results From the Phase 3 Program.
    Andorn A; Graham J; Csernansky J; Newcomer JW; Shinde S; Muma G; Heidbreder C; Fava M
    J Clin Psychopharmacol; 2019; 39(5):428-433. PubMed ID: 31343440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial.
    Correll CU; Skuban A; Ouyang J; Hobart M; Pfister S; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
    Am J Psychiatry; 2015 Sep; 172(9):870-80. PubMed ID: 25882325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
    Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L
    Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: An 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study.
    Isitt JJ; Nadipelli VR; Kouassi A; Fava M; Heidbreder C
    Schizophr Res; 2016 Jul; 174(1-3):126-131. PubMed ID: 27066860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exposure-response analysis after subcutaneous administration of RBP-7000, a once-a-month long-acting Atrigel formulation of risperidone.
    Ivaturi V; Gopalakrishnan M; Gobburu JVS; Zhang W; Liu Y; Heidbreder C; Laffont CM
    Br J Clin Pharmacol; 2017 Jul; 83(7):1476-1498. PubMed ID: 28133766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study.
    Casey DE; Sands EE; Heisterberg J; Yang HM
    Psychopharmacology (Berl); 2008 Oct; 200(3):317-31. PubMed ID: 18597078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study.
    Kane JM; Peters-Strickland T; Baker RA; Hertel P; Eramo A; Jin N; Perry PP; Gara M; McQuade RD; Carson WH; Sanchez R
    J Clin Psychiatry; 2014 Nov; 75(11):1254-60. PubMed ID: 25188501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
    Li H; Rui Q; Ning X; Xu H; Gu N
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia.
    Meltzer HY; Risinger R; Nasrallah HA; Du Y; Zummo J; Corey L; Bose A; Stankovic S; Silverman BL; Ehrich EW
    J Clin Psychiatry; 2015 Aug; 76(8):1085-90. PubMed ID: 26114240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.
    Modabbernia A; Rezaei F; Salehi B; Jafarinia M; Ashrafi M; Tabrizi M; Hosseini SM; Tajdini M; Ghaleiha A; Akhondzadeh S
    CNS Drugs; 2013 Jan; 27(1):57-65. PubMed ID: 23233269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.
    Loebel A; Cucchiaro J; Sarma K; Xu L; Hsu C; Kalali AH; Pikalov A; Potkin SG
    Schizophr Res; 2013 Apr; 145(1-3):101-9. PubMed ID: 23415311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia.
    Haas M; Unis AS; Armenteros J; Copenhaver MD; Quiroz JA; Kushner SF
    J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):611-21. PubMed ID: 20035579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial.
    Kane JM; Eshet R; Harary E; Tohami O; Elgart A; Knebel H; Sharon N; Suett M; Franzenburg KR; Davis GL; Correll CU
    CNS Drugs; 2024 Aug; 38(8):625-636. PubMed ID: 38954317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
    Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic.
    Kane JM; Eerdekens M; Lindenmayer JP; Keith SJ; Lesem M; Karcher K
    Am J Psychiatry; 2003 Jun; 160(6):1125-32. PubMed ID: 12777271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study.
    Savitz AJ; Lane R; Nuamah I; Gopal S; Hough D
    J Am Acad Child Adolesc Psychiatry; 2015 Feb; 54(2):126-137.e1. PubMed ID: 25617253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained-Release Risperidone via Subcutaneous Injection: A Systematic Review of RBP-7000 (PERSERIS
    Citrome L
    Clin Schizophr Relat Psychoses; 2018; 12(3):130-141. PubMed ID: 30339052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.